Great Valley Advisor Group Inc. Reduces Stake in Novo Nordisk A/S (NYSE:NVO)

Great Valley Advisor Group Inc. lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 5.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 34,905 shares of the company’s stock after selling 1,951 shares during the period. Great Valley Advisor Group Inc.’s holdings in Novo Nordisk A/S were worth $4,156,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. International Assets Investment Management LLC raised its stake in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the period. DSM Capital Partners LLC increased its holdings in shares of Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after buying an additional 1,593,303 shares during the last quarter. Mediolanum International Funds Ltd acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $98,765,000. Marshall Wace LLP raised its position in shares of Novo Nordisk A/S by 34,472.1% during the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock valued at $98,696,000 after buying an additional 689,441 shares during the period. Finally, Sanctuary Advisors LLC acquired a new position in Novo Nordisk A/S in the second quarter valued at approximately $41,646,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on NVO. BMO Capital Markets cut their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Trading Up 2.4 %

NVO opened at $105.06 on Friday. Novo Nordisk A/S has a 52 week low of $94.73 and a 52 week high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The business has a fifty day simple moving average of $115.48 and a 200-day simple moving average of $128.80. The firm has a market cap of $471.46 billion, a P/E ratio of 34.00, a P/E/G ratio of 1.32 and a beta of 0.42.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.